Fiera Capital Corp Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Fiera Capital Corp cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 3.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,257,964 shares of the company's stock after selling 39,338 shares during the quarter. Fiera Capital Corp owned approximately 1.69% of SpringWorks Therapeutics worth $40,305,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Lord Abbett & CO. LLC acquired a new stake in shares of SpringWorks Therapeutics during the first quarter valued at about $114,083,000. Price T Rowe Associates Inc. MD boosted its stake in shares of SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company's stock valued at $202,318,000 after purchasing an additional 1,333,892 shares in the last quarter. Duquesne Family Office LLC acquired a new stake in shares of SpringWorks Therapeutics during the second quarter valued at about $38,475,000. Maverick Capital Ltd. boosted its stake in shares of SpringWorks Therapeutics by 36.3% during the second quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company's stock valued at $97,962,000 after purchasing an additional 691,894 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of SpringWorks Therapeutics by 8.2% in the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company's stock worth $321,373,000 after acquiring an additional 492,783 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SWTX shares. JPMorgan Chase & Co. lifted their price objective on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 4th. HC Wainwright reiterated a "buy" rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Finally, Wedbush reiterated an "outperform" rating and issued a $77.00 target price on shares of SpringWorks Therapeutics in a report on Thursday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $68.50.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ SWTX traded up $0.90 during midday trading on Friday, hitting $33.99. 1,316,662 shares of the stock traded hands, compared to its average volume of 954,019. The company has a market cap of $2.52 billion, a PE ratio of -7.67 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a one year low of $18.00 and a one year high of $53.92. The business has a 50 day moving average price of $33.26 and a two-hundred day moving average price of $37.48.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million for the quarter, compared to the consensus estimate of $34.42 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. The company's revenue was up 59732900.0% compared to the same quarter last year. As a group, equities research analysts forecast that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.